Table: Santen Pharm -2021/22 group results (IFRS)
10/05/2022 07:00
May 10 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2022 Mar 31, 2021 Mar 31, 2023 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULT FORECAST H1 FORECAST
Sales 266.26 249.61 264.00
(+6.7 pct) (+3.3 pct) (-0.8 pct)
Operating 35.89 12.19 34.20
(+194.5 pct) (-63.7 pct) (-4.7 pct)
Pretax 35.62 11.69 32.50
(+204.7 pct) (-63.6 pct) (-8.7 pct)
Net 27.22 9.31
(+192.3 pct) (-60.6 pct)
EPS Basic 68.07 yen 23.30 yen 61.96 yen
EPS Diluted 67.97 yen 23.26 yen
Ann Div 32.00 yen 28.00 yen 32.00 yen
-Q2 Div 16.00 yen 14.00 yen 16.00 yen
-Q4 Div 16.00 yen 14.00 yen 16.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T